Alexithymia as predictor of treatment outcome in patients with functional gastrointestinal disorders

Piero Porcelli, R. Michael Bagby, Graeme J. Taylor, Massimo De Carne, Gioacchino Leandro, Orlando Todarello

Research output: Contribution to journalArticle

Abstract

Objective: A previous study found a strong association between alexithymia and functional gastrointestinal disorders (FGID). The objective of this study was to investigate whether alexithymia might be a predictor of treatment outcome in patients with FGID. Methods: A group of FGID outpatients classified by the 'Rome I' criteria was divided into improved (N = 68) and unimproved (N = 44) groups on the basis of pre-established criteria after 6 months of treatment. Patients were administered the 20-item Toronto Alexithymia Scale, the Hospital Anxiety and Depression Scale, and the Gastrointestinal Symptom Rating Scale both before and after 6 months of treatment. Results: At the base-line assessment, compared with the improved patients, the unimproved patients had significantly higher levels of anxiety, depression, alexithymia, and gastrointestinal symptoms. Stability of alexithymia was demonstrated by significant correlations between base-line and follow-up TAS-20 scores in the entire sample. Moreover, hierarchical regression analyses showed that the stability of TAS-20 scores over the 6-month treatment period could not be accounted for by their associations with anxiety and depression scores. In logistic regression analyses, base-line alexithymia and depression emerged as significant predictors of treatment outcome. Relative to depression, however, alexithymia was the stronger predictor. Conclusions: Alexithymia is a reliable and stable predictor of treatment outcome in FGID patients. Although further studies are needed, clinicians might improve treatment outcome by identifying patients with high alexithymia, and attempting to improve these patients' skills for coping with emotionally stressful situations.

Original languageEnglish
Pages (from-to)911-918
Number of pages8
JournalPsychosomatic Medicine
Volume65
Issue number5
DOIs
Publication statusPublished - Sep 2003

Fingerprint

Affective Symptoms
Gastrointestinal Diseases
Depression
Anxiety
Regression Analysis
Psychological Adaptation
Outpatients
Therapeutics
Logistic Models

Keywords

  • Alexithymia
  • Anxiety
  • Depression
  • Functional gastrointestinal disorders
  • Prediction
  • Treatment outcome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)

Cite this

Alexithymia as predictor of treatment outcome in patients with functional gastrointestinal disorders. / Porcelli, Piero; Bagby, R. Michael; Taylor, Graeme J.; De Carne, Massimo; Leandro, Gioacchino; Todarello, Orlando.

In: Psychosomatic Medicine, Vol. 65, No. 5, 09.2003, p. 911-918.

Research output: Contribution to journalArticle

Porcelli, Piero ; Bagby, R. Michael ; Taylor, Graeme J. ; De Carne, Massimo ; Leandro, Gioacchino ; Todarello, Orlando. / Alexithymia as predictor of treatment outcome in patients with functional gastrointestinal disorders. In: Psychosomatic Medicine. 2003 ; Vol. 65, No. 5. pp. 911-918.
@article{d41b063f5cc74e8288ef4effe2d4bad9,
title = "Alexithymia as predictor of treatment outcome in patients with functional gastrointestinal disorders",
abstract = "Objective: A previous study found a strong association between alexithymia and functional gastrointestinal disorders (FGID). The objective of this study was to investigate whether alexithymia might be a predictor of treatment outcome in patients with FGID. Methods: A group of FGID outpatients classified by the 'Rome I' criteria was divided into improved (N = 68) and unimproved (N = 44) groups on the basis of pre-established criteria after 6 months of treatment. Patients were administered the 20-item Toronto Alexithymia Scale, the Hospital Anxiety and Depression Scale, and the Gastrointestinal Symptom Rating Scale both before and after 6 months of treatment. Results: At the base-line assessment, compared with the improved patients, the unimproved patients had significantly higher levels of anxiety, depression, alexithymia, and gastrointestinal symptoms. Stability of alexithymia was demonstrated by significant correlations between base-line and follow-up TAS-20 scores in the entire sample. Moreover, hierarchical regression analyses showed that the stability of TAS-20 scores over the 6-month treatment period could not be accounted for by their associations with anxiety and depression scores. In logistic regression analyses, base-line alexithymia and depression emerged as significant predictors of treatment outcome. Relative to depression, however, alexithymia was the stronger predictor. Conclusions: Alexithymia is a reliable and stable predictor of treatment outcome in FGID patients. Although further studies are needed, clinicians might improve treatment outcome by identifying patients with high alexithymia, and attempting to improve these patients' skills for coping with emotionally stressful situations.",
keywords = "Alexithymia, Anxiety, Depression, Functional gastrointestinal disorders, Prediction, Treatment outcome",
author = "Piero Porcelli and Bagby, {R. Michael} and Taylor, {Graeme J.} and {De Carne}, Massimo and Gioacchino Leandro and Orlando Todarello",
year = "2003",
month = "9",
doi = "10.1097/01.PSY.0000089064.13681.3B",
language = "English",
volume = "65",
pages = "911--918",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Alexithymia as predictor of treatment outcome in patients with functional gastrointestinal disorders

AU - Porcelli, Piero

AU - Bagby, R. Michael

AU - Taylor, Graeme J.

AU - De Carne, Massimo

AU - Leandro, Gioacchino

AU - Todarello, Orlando

PY - 2003/9

Y1 - 2003/9

N2 - Objective: A previous study found a strong association between alexithymia and functional gastrointestinal disorders (FGID). The objective of this study was to investigate whether alexithymia might be a predictor of treatment outcome in patients with FGID. Methods: A group of FGID outpatients classified by the 'Rome I' criteria was divided into improved (N = 68) and unimproved (N = 44) groups on the basis of pre-established criteria after 6 months of treatment. Patients were administered the 20-item Toronto Alexithymia Scale, the Hospital Anxiety and Depression Scale, and the Gastrointestinal Symptom Rating Scale both before and after 6 months of treatment. Results: At the base-line assessment, compared with the improved patients, the unimproved patients had significantly higher levels of anxiety, depression, alexithymia, and gastrointestinal symptoms. Stability of alexithymia was demonstrated by significant correlations between base-line and follow-up TAS-20 scores in the entire sample. Moreover, hierarchical regression analyses showed that the stability of TAS-20 scores over the 6-month treatment period could not be accounted for by their associations with anxiety and depression scores. In logistic regression analyses, base-line alexithymia and depression emerged as significant predictors of treatment outcome. Relative to depression, however, alexithymia was the stronger predictor. Conclusions: Alexithymia is a reliable and stable predictor of treatment outcome in FGID patients. Although further studies are needed, clinicians might improve treatment outcome by identifying patients with high alexithymia, and attempting to improve these patients' skills for coping with emotionally stressful situations.

AB - Objective: A previous study found a strong association between alexithymia and functional gastrointestinal disorders (FGID). The objective of this study was to investigate whether alexithymia might be a predictor of treatment outcome in patients with FGID. Methods: A group of FGID outpatients classified by the 'Rome I' criteria was divided into improved (N = 68) and unimproved (N = 44) groups on the basis of pre-established criteria after 6 months of treatment. Patients were administered the 20-item Toronto Alexithymia Scale, the Hospital Anxiety and Depression Scale, and the Gastrointestinal Symptom Rating Scale both before and after 6 months of treatment. Results: At the base-line assessment, compared with the improved patients, the unimproved patients had significantly higher levels of anxiety, depression, alexithymia, and gastrointestinal symptoms. Stability of alexithymia was demonstrated by significant correlations between base-line and follow-up TAS-20 scores in the entire sample. Moreover, hierarchical regression analyses showed that the stability of TAS-20 scores over the 6-month treatment period could not be accounted for by their associations with anxiety and depression scores. In logistic regression analyses, base-line alexithymia and depression emerged as significant predictors of treatment outcome. Relative to depression, however, alexithymia was the stronger predictor. Conclusions: Alexithymia is a reliable and stable predictor of treatment outcome in FGID patients. Although further studies are needed, clinicians might improve treatment outcome by identifying patients with high alexithymia, and attempting to improve these patients' skills for coping with emotionally stressful situations.

KW - Alexithymia

KW - Anxiety

KW - Depression

KW - Functional gastrointestinal disorders

KW - Prediction

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0141857809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141857809&partnerID=8YFLogxK

U2 - 10.1097/01.PSY.0000089064.13681.3B

DO - 10.1097/01.PSY.0000089064.13681.3B

M3 - Article

C2 - 14508040

AN - SCOPUS:0141857809

VL - 65

SP - 911

EP - 918

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

IS - 5

ER -